TITLE

Susceptibility for Postmenopausal Osteoporosis: Interaction Between Genetic, Hormonal and Lifestyle Factors

AUTHOR(S)
Mezquita-Raya, Pedro; Muñoz-Torres, Manuel; Alonso, Guillermo; Luna, Juan; Quesada, Jose; Dorado, Gabriel; Luque-Recio, Fernando; Ruiz-Requena, Maria; Lopez-Rodriguez, Francisca; Escobar-Jiménez, Fernando
PUB. DATE
November 2004
SOURCE
Calcified Tissue International;Nov2004, Vol. 75 Issue 5, p373
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Although previous studies have established the importance of genetic, hormonal and lifestyle factors separately, the integral role of these factors on bone mass in postmenopausal women is still controversial. We examined the association of the collagen 1-alpha-1 gene (COLIA1) and vitamin D receptor gene (VDR) polymorphisms, s-IGF-I, s-25OHD and lifestyle factors with bone mineral density (BMD) in postmenopausal women. We determined anthropometric parameters, lifestyle factors, serum levels of IGF-I and 25OHD, the COLIA1 Sp1 (Mscl) and VDR (Bsml, Taql) polymorphisms by PCR and BMD by dual X-ray absorptiometry in 141 ambulatory postmenopausal Spanish women. There were significant linear correlations between S-25OHD and BMD and between s-IGF-I and BMD. BMD was statistically higher in active subjects. Of the three different polymorphisms, only the COLIA1 Sp1 polymorphism was significantly associated with BMD. In the logistic regression model, the COLIA1 Sp1 polymorphism, S-25OHD, s-IGF-I and physical activity variables were independently associated with osteoporosis. Our study shows that COLIA1 Sp1 polymorphism, S-25OHD and s-IGF-I serum levels and physical activity are independently associated with BMD in postmenopausal Spanish women.
ACCESSION #
15349874

 

Related Articles

  • Incidence and causes for failure of treatment of women with proven osteoporosis. Zafran, Noah; Liss, Zvi; Peled, Ronit; Sherf, Michael; Reuveni, Haim // Osteoporosis International;Nov2005, Vol. 16 Issue 11, p1375 

    The purpose of this study was to examine factors influencing women’s compliance with medical therapy for osteoporosis in Israel. The study population consisted of women diagnosed with osteoporosis using a DEXA examination in the year 2000. Medication purchases for a period of 13 months...

  • BONES OF CONTENTION. Weil, Andrew // Time International (South Pacific Edition);3/20/2006, Issue 11, p67 

    The article discusses various issues related to osteoporosis in women. It is a medically established fact that women face the risk of bone loss decades earlier than men do. Osteoporosis is strongly influenced by genetic factors. A recently released medical report suggests that supplemental...

  • Characterisation of Patients with Postmenopausal Osteoporosis in French Primary Healthcare. Blotman, Francis; Cortet, Bernard; Hilliquin, Pascal; Avouac, Bernard; Allaert, François-André; Pouchain, Denis; Gaudin, Anne-Françoise; Cotté, François-Emery; El Hasnaoui, Abdelkader // Drugs & Aging;2007, Vol. 24 Issue 7, p603 

    Background: The public health burden of osteoporosis is high, principally because of increased risk of fractures and associated morbidity, handicap and mortality. Osteoporotic fracture prevention is therefore an important public health goal. General practitioners (GPs) play a key role in the...

  • Intramuscular Neridronate in Postmenopausal Women with Low Bone Mineral Density. Adami, Silvano; Gatti, Davide; Bertoldo, Francesco; Sartori, Leonardo; Di Munno, Ombretta; Filipponi, Paolo; Marcocci, Claudio; Frediani, Bruno; Palummeri, Ernesto; Fiore, Carmelo; Costi, Daniele; Rossini, Maurizio // Calcified Tissue International;Nov2008, Vol. 83 Issue 5, p301 

    Compliance to osteoporosis treatment with oral bisphosphonates is very poor. Intermittent intravenous bisphosphonate is a useful alternative, but this route is not readily available. Neridronate, a nitrogen-containing bisphosphonate that can be given intramuscularly (IM), was tested in a phase 2...

  • Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis. Christiansen, Claus; Chesnut, III, Charles H.; Adachi, Jonathan D.; Brown, Jacques P.; Fernandes, César E.; Kung, Annie W. C.; Palacios, Santiago; Levine, Amy B.; Chines, Arkadi A.; Constantine, Ginger D. // BMC Musculoskeletal Disorders;2010, Vol. 11, p130 

    Background: We report the safety findings from a 3-year phase 3 study (NCT00205777) of bazedoxifene, a novel selective estrogen receptor modulator under development for the prevention and treatment of postmenopausal osteoporosis. Methods: Healthy postmenopausal osteoporotic women (N = 7,492;...

  • Ibandronate: A Review of its Use in the Management of Postmenopausal Osteoporosis. Frampton, James E.; Perry, Caroline M. // Drugs;2008, Vol. 68 Issue 18, p2683 

    Abstract Ibandronate (ibandronic acid; Bonviva®, Boniva®), a nitrogen-containing bisphosphonate available in once-monthly oral and quarterly intravenous formulations for intermittent administration, has been approved for the treatment of osteoporosis in postmenopausal women in the EU, the...

  • Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women. Dawson-Hughes, Bess; Dallal, Gerard E.; Krall, Elizabeth A.; Harris, Susan; Sokoll, Lori J.; Falconer, Gladys; Dawson-Hughes, B; Dallal, G E; Krall, E A; Harris, S; Sokoll, L J; Falconer, G // Annals of Internal Medicine;10/1/91, Vol. 115 Issue 7, p505 

    Objectives: To determine whether relative vitamin D deficiency during the winter months contributes to age-related bone loss and whether rates of change in hard- and soft-tissue mass vary during the year. Design: Double-blind, placebo-controlled, 1-year trial in 249...

  • Amgen: Prolia delay further dampens expectations of hyped drug.  // PharmaWatch: Biotechnology;Dec2009, Vol. 8 Issue 12, p10 

    In this article the author examines the Food and Drug Administration's (FDA) request for additional data before approving Amgen Inc.'s Prolia for the treatment and prevention of osteoporosis in the U.S. The author says that under the request Amgen should provide more information about the design...

  • NEW FORMULATIONS.  // Drug Topics;5/16/2005, Vol. 149 Issue 10, p52 

    This article focuses on the approval of the Fosamax Plus D of Merck & Co. Inc. as treatment for women with osteoporosis. Fosamax is significant in reducing the risk of hip and spine fractures. The author claimed that the drug can increase the bone mass in men with osteoporosis.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics